CANTOURAGE GROUP SE O.N. (HIGH.F) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · Germany · ISIN DE000A3DSV01
CANTOURAGE GROUP SE O.N. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.20 m EUR | 3.91 m EUR |
| Operating income | 117,635.00 EUR | 186,106.00 EUR |
| Net income | 79,293.00 EUR | 126,458.00 EUR |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CANTOURAGE GROUP SE O.N.
Cantourage Group SE, a medical cannabis company, produces and distributes medical cannabis preparations and cannabis-based pharmaceuticals in Europe and internationally. The company offers cannabis dried flowers, extracts, dronabinol/tetrahydrocannabinol (THC), and cannabidiol (CBD) products. It exports its products to other European countries. The company distributes its products through pharmacies, wholesalers, and partners. Cantourage Group SE was founded in 2019 and is headquartered in Berlin, Germany.
More stocks
- Haivision Systems Inc (HAI.TO)
- PT Cerestar Indonesia Tbk (TRGU.JK)
- Jayjun Co Ltd (025620.KS)
- Kyobo 10 Special Purpose Acquisition Co. (355150.KQ)
- TOPTEC Co. Ltd (108230.KQ)
- Lebledor F&B Co., Ltd. (7757.TWO)
- Nanoform Finland Plc (NANOFH.HE)
- MARX Biotech Co., Ltd. (7731.TWO)
- LION COPPER & GOLD CORP. (LCGMF)
- TECOGEN INC. (TGEN)
- Evertex Fabrinology Ltd (1470.TW)
- Lumir Inc. (474170.KQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.